Vir Biotechnology is a clinical-stage biopharmaceutical company discovering and developing medicines for serious infectious diseases and cancer by harnessing the immune system, with a portfolio that includes programs for chronic hepatitis delta, dual-masked T-cell engagers for solid tumors, and preclinical programs across infectious diseases and oncologic indications. The company generates revenue through license and collaboration agreements with partners such as Norgine, GSK, Alnylam, and Xencor—which provide upfront payments, milestone achievements, and royalties on net sales—as well as grant funding from the Bill & Melinda Gates Foundation and the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority. Vir holds exclusive rights to the PRO-XTEN® masking platform for oncology and infectious disease applications and operates primarily in the United States with foreign subsidiaries.